Guangdong Maiheng Pharmaceutical

Guangdong Maiheng Pharmaceutical is a clinical-stage biopharmaceutical company headquartered in Guangzhou, China, specializing in the discovery and development of innovative small molecule therapeutics. The company's research efforts are primarily directed toward immunology, inflammation, and metabolic disorders. Its lead pipeline candidate, MH-004, is a selective Janus kinase 1 (JAK1) inhibitor being developed for the treatment of atopic dermatitis and other autoimmune conditions. Maiheng aims to provide high-quality, affordable innovative medicines through its integrated R&D and manufacturing platform. The company is recognized as a High-Tech Enterprise and operates within the Guangzhou International Bio-Island biotech cluster.